probenecid has been researched along with Sarcoma 180 in 1 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
Sarcoma 180: An experimental sarcoma of mice.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sirotnak, FM | 1 |
| Moccio, DM | 1 |
| Hancock, CH | 1 |
| Young, CW | 1 |
1 other study available for probenecid and Sarcoma 180
| Article | Year |
|---|---|
Improved methotrexate therapy of murine tumors obtained by probenecid-mediated pharmacological modulation at the level of membrane transport.
Topics: Animals; Biological Transport, Active; Bone Marrow; Female; Kidney; Kinetics; Leukemia L1210; Liver; | 1981 |